** Eli Lilly LLY.N on Thursday suggested that demand for Mounjaro and Zepbound, its popular diabetes and weight-loss treatments, was not a concern, easing investor agitation about signs of weakness in sales of the drugs
** Stock up 0.4% at $873.51 in premarket trading
** Average rating of 28 analysts on Lilly is the equivalent of "buy" and their median PT is $988.50, LSEG data shows
A HEALTHY BOTTOM LINE
** J.P.Morgan ("overweight," PT: $1,100) expects Mounjaro sales to surge ~240% to $64 bln from 2025-2030 and Zepbound sales to rocket ~430% to $64 bln in the same period, driven by greater access/penetration
** Morningstar (fair value: $620) thinks the GLP-1 market could exceed $75 billion in 2025 and expects LLY's sales to increase by $13 bln, outpacing Novo's NOVOb.CO $9 bln growth
** Truist Securities ("buy," PT: $1,038) sees growth in oncology, immunology and neuroscience, boosting revenue and margins driven by recent approvals of Omvoh (Crohn's disease), Ebglyss (Eczema), Kisunla (Alzheimer's), Zepbound (sleep apnea)
** Jefferies ("buy," PT: $1,020) sees orforglipron (orfo), an oral drug for diabetes and obesity, showing Wegovy-like safety and efficacy heading into late-stage tests
(Reporting by Akriti Shah in Bengaluru)
((akriti.shah@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.